Substituted 1,2,3,4-tetrahydroisoquinolines with angiotensin II receptor antagonist properties
AssigneeWarner-Lambert Company
InventorsClifton J. Blankley, John C. Hodges, Sylvester Klutchko
Life of this patent
Estimating the term…
Abstract
This invention relates to novel substituted 1,2,3,4-tetrahydroisoquinolines which are useful the treatment of vascular restenosis, various disorders of the central nervous system, in the regulation of female reproductive functions, in cognitive enhancement, in atherosclerosis and in treating excessive AVP secretory disorders. Novel intermediates useful in the preparation of the compounds are also disclosed. Methods of using the compounds and pharmaceutical compositions containing them are disclosed.
Claims5
A method for treating cognitive decline in a mammal suffering therefrom comprising administering to said mammal a therapeutically effective amount of a compound of Formula I ##STR58## or a pharmaceutically acceptable salt thereof wherein:
- R.sub.1 and R.sub.2 are each indepdendently hydrogen, lower alkyl, halogen, hydroxy, alkoxy, amino, alkylamino, dialkylamino, acylamino, CF.sub.3, carboxy, carboalkoxy, hydroxyalkyl, aminoalkyl, and nitro;
- n is an integer from zero to 4;
- X is absent, O, S, NH, N-alkyl, and is attached to the tetrahydroisoquinoline at the 5 to 6 position;
- R.sub.3 is hydrogen, alkoxy, aralkoxy, alkylthio, or halogen;
- R.sub.4 is hydrogen, alkyl, hydroxyalkyl, CO.sub.2 R.sub.6, CON(R.sub.6).sub.2 wherein
- R.sub.6 is hydrogen or lower alkyl;
- and
- R.sub.5 is alkyl, aryl, aralkyl which can be unsubstituted or substituted on the alkyl and/or on the aryl portion, diaralkyl, the aryl portion can be unsubstituted or substituted, COR.sub.7, SO.sub.2 R.sub.7 wherein R.sub.7 is aralkyl, alkyl, diaralkyl, OR.sub.8, NR.sub.8 R.sub.9 wherein R.sub.8 and R.sub.9 are each independently hydrogen, alkyl, cycloalkyl, aryl, or aralkyl wherein aryl is phenyl or naphthyl and the substituents are one or more selected from:
- alkyl, alkoxy, hydroxy, halogen, NO.sub.2, NH.sub.2, NHalkyl, N(alkyl).sub.2, SCH, and SH.
A method for treating atherosclerosis in a mammal suffering therefrom which comprises administering a therapeutically effective amount of a compound of Formula I ##STR59## or a pharmeceutically acceptable salt thereof wherein:
- R.sub.1 and R.sub.2 are each independently hydrogen, lower alkyl, halogen, hydroxy, alkoxy, amino, alkylamino, dialkylamino, acylamino, CF.sub.3, carboxy, carboalkoxy, hydroxyalkyl, aminoalkyl, and nitro;
- n is an integer from zero to 4;
- X is absent, O, S, NH, N-alkyl, and is attached to the tetrahydroisoquinoline at the 5 or 6 position;
- R.sub.3 is hydrogen, alkoxy, aralkoxy, alkylthio, or halogen;
- R.sub.4 is hydrogen, alkyl, hydroxyalkyl, CO.sub.2 R.sub.6, CON(R.sub.6).sub.2 wherein
- R.sub.6 is hydrogen or lower alkyl;
- and
- R.sub.5 is alkyl, aryl, aralkyl which can be unsubstituted or substituted on the alkyl and/or on the aryl portion, diaralkyl, the aryl portion can be unsubstituted or substituted, COR.sub.7, SO.sub.2 R.sub.7 wherein R.sub.7 is aralkyl, alkyl, diaralkyl, OR.sub.8, NR.sub.8 R.sub.9 wherein R.sub.8 and R.sub.9 are each independently hydrogen, alkyl, cycloalkyl, aryl, or aralkyl wherein aryl is phenyl or naphthyl and the substituents are one or more selected from:
- alkyl, alkoxy, hydroxy, halogen, NO.sub.2, NH.sub.2, NHalkyl, N(alkyl).sub.2, SCH, and SH.
A method for treating female reproductive disorders is a mammal suffering therefrom which comprises administering a therapeutically effective amount of a compound of Formula I ##STR60## or a pharmaceutically acceptable salt thereof wherein:
- R.sub.1 and R.sub.2 are each independently hydrogen, lower alkyl, halogen, hydroxy, alkoxy, amino, alkylamino, dialkylamino, acylamino, CF.sub.3, carboxy, carboalkoxy, hydroxyalkyl, aminoalkyl, and nitro;
- n is an integer from zero to 4;
- X is absent, O, S, NH, N-alkyl, and is attached to the tetrahydroisoquinoline at the 5 to 6 position;
- R.sub.3 is hydrogen, alkoxy, aralkoxy, alkylthio, or halogen;
- R.sub.4 is hydrogen, alkyl, hydroxyalkyl, CO.sub.2 R.sub.6, CON(R.sub.6).sub.2 wherein
- R.sub.6 is hydrogen or lower alkyl;
- and
- R.sub.5 is alkyl, aryl, aralkyl which can be unsubstituted or substituted on the alkyl and/or on the aryl position, diaralkyl, the aryl portion can be unsubstituted or substituted, COR.sub.7, SO.sub.2 R.sub.7 wherein R.sub.7 is aralkyl, alkyl, diaralkyl, OR.sub.8, NR.sub.8 R.sub.9 wherein R.sub.8 and R.sub.9 are each independently hydrogen, alkyl, cycloalkyl, aryl, or aralkyl wherein aryl is phenyl or naphthyl and the substituents are one or more selected from:
- alkyl, alkoxy, hydroxy, halogen, NO.sub.2, NH.sub.2, NHalkyl, N(alkyl).sub.2, SCH, and SH.
A method for treating depression in a mammal suffering therefrom which comprises administering a therapeutically effective amount of a compound of Formula I ##STR61## or a pharmaceutically acceptable salt thereof wherein:
- R.sub.1 and R.sub.2 are each independently hydrogen, lower alkyl, halogen, hydroxy, alkoxy, amino, alkylamino, dialkylamino, acylamino, CF.sub.3, carboxy, carboalkoxy, hydroxyalkyl, aminoalkyl, and nitro;
- n is an integer from zero to 4;
- X is absent, O, S, NH, N-alkyl, and is attached to the tetrahydroisoquinoline at the 5 or 6 position;
- R.sub.3 is hydrogen, alkoxy, aralkoxy, alkylthio, or halogen;
- R.sub.4 is hydrogen, alkyl, hydroxyalkyl, CO.sub.2 R.sub.6, CON(R.sub.6).sub.2 wherein
- R.sub.6 is hydrogen or lower alkyl;
- and
- R.sub.5 is alkyl, aryl, aralkyl which can be unsubstituted or substituted on the alkyl and/or on the aryl portion, diaralkyl, the aryl portion can be unsubstituted or substituted, COR.sub.7, SO.sub.2 R.sub.7 wherein R.sub.7 is aralkyl, alkyl, diaralkyl, OR.sub.8, NR.sub.8 R.sub.9 wherein R.sub.8 and R.sub.9 are each independently hydrogen, alkyl, cycloalkyl, aryl, or aralkyl wherein aryl is phenyl or naphthyl and the substituents are one or more selected from:
- alkyl, alkoxy, hydroxy, halogen, NO.sub.2, NH.sub.2, NHalkyl, N(alkyl).sub.2, SCH, and SH.
A method for treating vascular and cardiac hypertrophy in a mammal suffering therefrom which comprises administering a therapeutically effective amount of a compound of Formula I ##STR62## or a pharmaceutically acceptable salt thereof wherein:
- R.sub.1 and R.sub.2 are each independently hydrogen, lower alkyl, halogen, hydroxy, alkoxy, amino, alkylamino, dialkylamino, acylamino, CF.sub.3, carboxy, carboalkoxy, hydroxyalkyl, aminoalkyl, and nitro;
- n is an integer from zero to 4;
- X is absent, O, S, NH, N-alkyl, and is attached to the tetrahydroisoquinoline at the 5 to 6 position;
- R.sub.3 is hydrogen, alkoxy, aralkoxy, alkylthio, or halogen;
- R.sub.4 is hydrogen, alkyl, hydroxyalkyl, CO.sub.2 R.sub.6, CON(R.sub.6).sub.2 wherein
- R.sub.6 is hydrogen or lower alkyl;
- and
- R.sub.5 is alkyl, aryl, aralkyl which can be unsubstituted or substituted on the alkyl and/or on the aryl portion, diaralkyl, the aryl portion can be unsubstituted or substituted, COR.sub.7, SO.sub.2 R.sub.7 wherein R.sub.7 is aralkyl, alkyl, diaralkyl, OR.sub.8, NR.sub.8 R.sub.9 wherein R.sub.8 and R.sub.9 are each independently hydrogen, alkyl, cycloalkyl, aryl, or aralkyl wherein aryl is phenyl or naphthyl and the substituents are one or more selected from:
- alkyl, alkoxy, hydroxy, halogen, NO.sub.2, NH.sub.2, NHalkyl, N(alkyl).sub.2, SCH, and SH.
Dependencies are inferred from the claim text.